Bio­gen makes a buy­out deal, but it’s not the big one you’ve been wait­ing for

8 years ago
Pharma

Eli Lil­ly fi­nal­ly pub­lished its dis­as­trous EX­PE­DI­TION3 da­ta, a cost­ly les­son in re­think­ing Alzheimer's

8 years ago
R&D

In a break­through, Chi­nese re­searchers clone mon­keys hop­ing to pro­vide bet­ter dis­ease mod­els

8 years ago
China

GW on fire: PhI­II epilep­sy da­ta sig­nals suc­cess ahead for first CBD drug

8 years ago
R&D

No­var­tis steps in to grab ex-US rights to pi­o­neer­ing gene ther­a­py Lux­tur­na with $170M deal

8 years ago
R&D
Pharma

Ex-Al­ler­gan team at Bon­ti rais­es $15.5M for an­oth­er neu­ro­tox­in; Shire com­mits to pub­lish­ing in open ac­cess jour­nals ...

8 years ago
News Briefing

The new se­r­i­al en­tre­pre­neur in the biotech are­na launch­es an­oth­er up­start look­ing to drug RNA

8 years ago
Startups

Pfiz­er’s lat­est copy­cat could put the squeeze on Roche — again

8 years ago
R&D
Pharma

Big day loom­ing, No­var­tis' new CEO Vas Narasimhan read­ies his jump in­to a mar­ket­ing melee

8 years ago
Bioregnum
Opinion

When VCs hand out mega-rounds to Vir and Gos­samer, are they bet­ting on the jock­ey or the horse?

8 years ago
Financing
Startups

Reck­on­ing the po­ten­tial of CRISPR/Cas9 tech, NIH launch­es $190M genome edit­ing re­search ini­tia­tive

8 years ago
R&D
Discovery

Puma Biotech­nol­o­gy shares tank af­ter CHMP looks ready to hit a red light on ner­a­tinib

8 years ago
Pharma

In­cyte tries to fend off TR­C's mi­ni-ten­der of­fer to in­vestors; Grit­stone On­col­o­gy scoops Acte­lion CFO Jean-Marc ...

8 years ago
News Briefing

Pan­cre­at­ic can­cer com­bo sees high sur­vival rates in Chemo­Cen­tryx PhIb da­ta

8 years ago
R&D

J&J’s move to cut Rem­i­cade price cost some big bucks, but guard­ed against Pfiz­er’s copy­cat

8 years ago
R&D
Pharma

Al­lied with Penn, Tmu­ni­ty’s cell ther­a­py pi­o­neers bag $100M mega-round to back a break­through quest on CAR-T, ...

8 years ago
Startups

Lin­ing up against ri­vals, Am­gen and No­var­tis build a block­buster case for their CGRP mi­graine drug

8 years ago
R&D

Top 10 pipeline blowups, set­backs and sna­fus in H2 2017

8 years ago
Bioregnum
R&D

FDA slaps down Brae­burn on opi­oid ad­dic­tion drug, putting In­di­v­ior and Alk­er­mes in strong po­si­tion

8 years ago
Pharma

Fast-grow­ing Gilead buys an R&D cam­pus for $135M — re­port; Eu­re­ka bags $60M round for T cell R&D work

8 years ago
News Briefing

Gov­ern­ment shut­down to end - at least tem­porar­i­ly - as Dems take Mc­Connell at his word

8 years ago
Pharma

What are the top 10 cor­po­rate VCs in bio­phar­ma to­day? And what do they want to fund — or steer clear of?

8 years ago
Financing

Idera, Biocryst to merge, re­brand and fo­cus in rare dis­ease pro­grams

8 years ago
Deals

Hep­tares co-founder Fiona Mar­shall grabs the helm at Mer­ck­'s up­com­ing UK drug dis­cov­ery cen­ter

8 years ago
People
First page Previous page 1066106710681069107010711072 Next page Last page
A service from the Financial Times